305 related articles for article (PubMed ID: 30795566)
1. Prognostic Factors of Early Stage Epithelial Ovarian Carcinoma.
Hsieh SF; Lau HY; Wu HH; Hsu HC; Twu NF; Cheng WF
Int J Environ Res Public Health; 2019 Feb; 16(4):. PubMed ID: 30795566
[TBL] [Abstract][Full Text] [Related]
2. Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma - A multi-institutional cohort.
Prendergast EN; Holzapfel M; Mueller JJ; Leitao MM; Gunderson CC; Moore KN; Erickson BK; Leath CA; Diaz Moore ES; Cohen JG; Walsh CS
Gynecol Oncol; 2017 Feb; 144(2):274-278. PubMed ID: 27979319
[TBL] [Abstract][Full Text] [Related]
3. Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review.
García-Sáenz JA; Custodio A; Casado A; Vidart JA; Coronado PJ; Martín M; López-Tarruella S; Puente J; Fernández C; Díaz-Rubio E
Clin Transl Oncol; 2011 Feb; 13(2):121-32. PubMed ID: 21324801
[TBL] [Abstract][Full Text] [Related]
4. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
[TBL] [Abstract][Full Text] [Related]
5. Survival benefit of patients with early-stage ovarian carcinoma treated with paclitaxel chemotherapeutic regimens.
Chen CA; Chiang CJ; Chen YY; You SL; Hsieh SF; Tang CH; Cheng WF
J Gynecol Oncol; 2018 Jan; 29(1):e16. PubMed ID: 29185274
[TBL] [Abstract][Full Text] [Related]
6. Intraoperative Capsule Rupture, Postoperative Chemotherapy, and Survival of Women With Stage I Epithelial Ovarian Cancer.
Matsuo K; Machida H; Yamagami W; Ebina Y; Kobayashi Y; Tabata T; Kaneuchi M; Nagase S; Enomoto T; Mikami M
Obstet Gynecol; 2019 Nov; 134(5):1017-1026. PubMed ID: 31599824
[TBL] [Abstract][Full Text] [Related]
7. Potential risk factors associated with prognosis of neoadjuvant chemotherapy followed by interval debulking surgery in stage IIIc-IV high-grade serous ovarian carcinoma patients.
Zhang J; Liu N; Zhang A; Bao X
J Obstet Gynaecol Res; 2018 Sep; 44(9):1808-1816. PubMed ID: 30019801
[TBL] [Abstract][Full Text] [Related]
8. Delay in adjuvant chemotherapy administration for patients with FIGO stage I epithelial ovarian carcinoma is associated with worse survival; an analysis of the National Cancer Database.
Nasioudis D; Mastroyannis SA; Ko EM; Haggerty AF; Cory L; Giuntoli RL; Kim SH; Morgan MA; Latif NA
Gynecol Oncol; 2022 Aug; 166(2):263-268. PubMed ID: 35667901
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant taxane plus platinum chemotherapy for stage I ovarian clear cell carcinoma with complete surgical staging: are more than three cycles necessary?
Ukai M; Suzuki S; Yoshihara M; Yokoi A; Yoshikawa N; Kajiyama H; Kikkawa F
Int J Clin Oncol; 2022 Mar; 27(3):609-618. PubMed ID: 34779959
[TBL] [Abstract][Full Text] [Related]
10. [Clinicopathologic and survival analysis of synchronous primary endometrial and ovarian cancer].
Wang Y; Yu M; Yang JX; Cao DY; Zhang Y; Shen K; You Y
Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):816-822. PubMed ID: 30585019
[No Abstract] [Full Text] [Related]
11. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
12. Impact of young age on platinum response in women with epithelial ovarian cancer: Results of a large single-institution registry.
Michels J; Genestie C; Dunant A; Caron O; Lanoy E; Colomba E; Pommeret F; Rey A; Gouy S; Duvillard P; Teuff GL; Larue C; Savoye AM; Lhommé C; Leary A; Morice P; Pautier P
Gynecol Oncol; 2021 Jan; 160(1):77-82. PubMed ID: 33059915
[TBL] [Abstract][Full Text] [Related]
13. A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy.
Previs RA; Bevis KS; Huh W; Tillmanns T; Perry L; Moore K; Chapman J; McClung C; Kiet T; Java J; Chan J; Secord AA
Gynecol Oncol; 2014 Mar; 132(3):531-6. PubMed ID: 24472410
[TBL] [Abstract][Full Text] [Related]
14. Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment.
Yalcin I; Meydanli MM; Turan AT; Taskin S; Sari ME; Gungor T; Akbayir O; Ayhan A
Int J Clin Oncol; 2018 Apr; 23(2):329-337. PubMed ID: 29143144
[TBL] [Abstract][Full Text] [Related]
15. Impact of the number of cycles of platinum-based chemotherapy for early stage ovarian clear cell carcinoma on survival: a retrospective study.
Gao Y
BMC Womens Health; 2023 May; 23(1):262. PubMed ID: 37189098
[TBL] [Abstract][Full Text] [Related]
16. The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG Oncology/Gynecologic Oncology Group trials.
Chan JK; Java JJ; Fuh K; Monk BJ; Kapp DS; Herzog T; Bell J; Young R
Gynecol Oncol; 2016 Dec; 143(3):490-495. PubMed ID: 27771168
[TBL] [Abstract][Full Text] [Related]
17. The prognostic significance of preoperative leukocytosis in epithelial ovarian carcinoma: a retrospective cohort study.
So KA; Hong JH; Jin HM; Kim JW; Song JY; Lee JK; Lee NW
Gynecol Oncol; 2014 Mar; 132(3):551-5. PubMed ID: 24440470
[TBL] [Abstract][Full Text] [Related]
18. Is there a high-risk subgroup of stage I epithelial ovarian cancer that is most likely to benefit from 6 versus 3 cycles of adjuvant chemotherapy?
Bakkum-Gamez JN; Richardson DL; Seamon LG; Aletti GD; Powless CA; Keeney GL; O'Malley DM; Cliby WA
Int J Gynecol Cancer; 2010 Oct; 20(7):1125-31. PubMed ID: 21495213
[TBL] [Abstract][Full Text] [Related]
19. Survival impact of low anterior resection in patients with epithelial ovarian cancer grossly confined to the pelvic cavity: a Korean multicenter study.
Kim M; Suh DH; Park JY; Paik ES; Lee S; Eoh KJ; Nam JH; Lee YY; Kim JW; Kim S
J Gynecol Oncol; 2018 Jul; 29(4):e60. PubMed ID: 29770630
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors for maximally or optimally cytoreduced stage III nonserous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy.
Cuylan ZF; Meydanli MM; Sari ME; Akbayir O; Celik H; Dede M; Sahin H; Gungorduk K; Kuscu E; Ozgul N; Gungor T; Ayhan A
J Obstet Gynaecol Res; 2018 Jul; 44(7):1284-1293. PubMed ID: 29727055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]